The device-maker's floor — ≥$5.90, locked at 88%.

88% probability Medtronic keeps its fiscal-2027 adjusted EPS guidance floor at or above $5.90 at its first-quarter results — the low end of the range set in June, against 6.75–7.25% organic revenue growth guidance. Resolves ~1 Sep 2026.

Type · Prediction Lock · guidance-floor maintenance Locked · 2026-08-13 · before the Q1 FY2027 results Resolves · ~2026-09-01 · Medtronic Q1 FY2027 results (medtronic.com) Scored · binary: FY2027 adjusted EPS guidance floor ≥$5.90 yes/no

Medtronic FY2027 adjusted EPS floor · our locked threshold

≥ $5.90

per share · low end of the $5.90–$6.00 guide

Medtronic guided fiscal-2027 adjusted EPS to $5.90–$6.00, a midpoint of $5.95 that sat below the $6.06 analyst consensus, alongside organic revenue growth guidance of 6.75–7.25%, after delivering its highest annual revenue growth in ten years in FY2026. Source: Medtronic FY2026 fourth-quarter results, 3 June 2026.

— 1 · The Locked Call

Medtronic's FY2027 adjusted EPS guidance floor stays ≥$5.90 — P = 0.88.

We lock a binary: Medtronic's fiscal-2027 adjusted EPS guidance floor is at or above $5.90 as stated at its first-quarter FY2027 results. Confidence 88%.

— 2 · Why it's nail-able

The guidance was set conservatively below consensus only one quarter earlier.

Medtronic set this range in June at a $5.95 midpoint that deliberately sat below the $6.06 analyst consensus, after delivering its strongest annual revenue growth in a decade. Guidance pitched below the Street at the start of a year is rarely cut one quarter in. Confidence 88%, not higher, because medical-device revenue carries real currency translation exposure and a single reimbursement or regulatory setback can force a revision. Scored on the GUIDANCE RANGE stated in the Q1 release, not on reported quarterly EPS.

Locked on 2026-08-13 — scored against Medtronic's stated FY2027 guidance at Q1.

RAOSCAFF locks P-167 on 2026-08-13, before the Q1 FY2027 release. Scored against the low end of Medtronic's fiscal-2027 adjusted EPS guidance as stated at its first-quarter results.

Locked: 2026-08-13 (commit timestamp on origin/main)
Resolves: ~2026-09-01 — Medtronic Q1 FY2027 results (quarter ended 31 July 2026)
Source: Medtronic Q1 FY2027 earnings release, fiscal-2027 adjusted EPS guidance range (medtronic.com; news.medtronic.com)
Scored by: Binary: YES if the FY2027 adjusted EPS guidance floor stated at Q1 is ≥$5.90; NO if lowered below $5.90 or withdrawn. Scored on GUIDANCE, not on reported quarterly EPS.

Currency translation and a reimbursement or regulatory setback are the disclosed tails.